ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
Status: Recruiting
Location: See all (28) locations...
Study Type: Observational
SUMMARY
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: f
View:
• Documented diagnosis of AHP, per physician's determination
Locations
United States
Alabama
Clinical Trial Site
RECRUITING
Birmingham
Arizona
Clinical Trial Site
RECRUITING
Gilbert
California
Clinical Trial Site
RECRUITING
San Francisco
Massachusetts
Clinical Trial Site
RECRUITING
Boston
Maryland
Clinical Trial Site
RECRUITING
Baltimore
Minnesota
Clinical Trial Site
RECRUITING
Minneapolis
North Carolina
Clinical Trial Site
RECRUITING
Winston-salem
New York
Clinical Trial Site
RECRUITING
New York
Oklahoma
Clinical Trial Site
RECRUITING
Oklahoma City
Pennsylvania
Clinical Trial Site
RECRUITING
Philadelphia
Texas
Clinical Trial Site
RECRUITING
Galveston
Utah
Clinical Trial Site
RECRUITING
Salt Lake City
Washington
Clinical Trial Site
RECRUITING
Seattle
Other Locations
Belgium
Clinical Trial Site
RECRUITING
Leuven
France
Clinical Trial Site
RECRUITING
Bordeaux
Clinical Trial Site
RECRUITING
Paris
Clinical Trial Site
RECRUITING
Toulouse
Germany
Clinical Trial Site
RECRUITING
Chemnitz
Clinical Trial Site
RECRUITING
Münster
Clinical Trial Site
RECRUITING
Würzburg
Italy
Clinical Trial Site
RECRUITING
Milan
Clinical Trial Site
RECRUITING
Modena
Sweden
Clinical Trial Site
RECRUITING
Stockholm
Switzerland
Clinical Trial Site
RECRUITING
Zürich
Taiwan
Clinical Trial Site
RECRUITING
Taichung
Clinical Trial Site
RECRUITING
Taipei
United Kingdom
Clinical Trial Site
RECRUITING
Cardiff
Clinical Trial Site
RECRUITING
London
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2021-04-26
Estimated Completion Date: 2027-04-01
Participants
Target number of participants: 150
Treatments
Patients with AHP
Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals